Yale school

Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, April 2, 2024
Uterus, Gynaecology, Longevity, Reproductive Sciences, Patient, Collaboration, University, EMA, MD, European Medicines Agency, European, PIPE, Esophageal atresia, Yale school, OTCQB, Cryptocurrency

The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.

Key Points: 
  • The EMA is the centralized regulatory agency for the review and approval of new medicines in the European Union.
  • Company’s subsidiary in Hong Kong launched its longevity product business in Asia, generating more than $100,000 in 2023 sales.
  • Entered into securities purchase agreements with accredited investors for a $6 million private investment in public equity (PIPE) financing.
  • Holliston, MA, April 02, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported fourth quarter and full year 2023 financial results.

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, April 1, 2024
Employment, Brain, ALS, Patient, CNS, SVP, Cell biology, Bristol Myers Squibb, University, Initial, Myelocyte, Therapy, Drug development, Alkahest, Yale school, Clinical neuroscience, Compensated emancipation, Pharmaceutical industry

“I am pleased to welcome Jonas to Gain and look forward to his contributions.

Key Points: 
  • “I am pleased to welcome Jonas to Gain and look forward to his contributions.
  • His academic work focused on immuno-neurology, particularly on the effect of systemic inflammation on myeloid cells in the brain.
  • Previously, he served as Chief Medical Officer at Tranquis Therapeutics and Capacity Bio, SVP of Clinical Development at Alkahest, Medical Director at Denali Therapeutics, and Director of Neuroscience Discovery Medicine at UCB Pharma.
  • “Looking at the extensive data package that the Gain team has generated during preclinical development, Gain’s lead drug candidate GT-02287 has a first and best-in-class profile.

Gennao Bio Debuts Preclinical Data for First-in-Class Antibody-Drug Conjugate from Gene Monoclonal Antibody Platform (GMAB ADC)

Retrieved on: 
Tuesday, April 9, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Human, Plasma, Survival, Yale University, Colorectal cancer, Neoplasm, DNA, Hepatotoxicity, Biology, AACR, ENT2, Cytoplasm, Yale school, Therapy, Poster, ADC, Vaccine

Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced new preclinical results on the application of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology as an antibody-drug conjugate (ADC) for the treatment of solid tumors.

Key Points: 
  • Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced new preclinical results on the application of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology as an antibody-drug conjugate (ADC) for the treatment of solid tumors.
  • The data were presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • In preclinical studies, our GMAB technology demonstrated selective delivery of payloads into tumors by targeting ENT2, a nucleoside transporter that is highly overexpressed in many tumors.
  • “These preclinical results reinforce the versatility of the GMAB platform and its ability to deliver therapeutic payloads beyond genetic medicine to targeted tissue,” Chris Duke, chief executive officer of Gennao.

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Retrieved on: 
Wednesday, March 13, 2024
Dopamine, NET, Reward, Sheba Medical Center, CWY, Psychiatry, Serotonin, Patient, Research, MEAI, Alcoholism, Clinical trial, DAT, Safety, Norepinephrine, Yale school, Therapy, Ministry, Pharmaceutical industry

The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.

Key Points: 
  • The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.
  • The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Stroke, Brain, Patient, Concussion, TBI, Death, IND, Traumatic brain injury, Investigational New Drug, Yale school, FDA, Health, Food, Pharmaceutical industry

The IND application clearance also paves the way for additional studies further exploring AST-004 in stroke, as well as TBI, and concussion.

Key Points: 
  • The IND application clearance also paves the way for additional studies further exploring AST-004 in stroke, as well as TBI, and concussion.
  • And it has the potential to treat stroke occurring in any sized blood vessel in the brain.
  • Astrocyte previously completed two Phase 1 safety trials in Europe, involving 80 participants in total, and saw no significant adverse effects or safety concerns.
  • Dr. William Korinek, CEO of Astrocyte Pharmaceuticals, commented, “Since our founding in 2014, we have been focused on demonstrating the potential of cerebroprotective benefits of AST-004.

Gennao Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Neoplasm, Radiology, AACR, Yale school, Therapy, ADC, Vaccine

Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that an abstract reporting preclinical results of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA.

Key Points: 
  • Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that an abstract reporting preclinical results of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA.
  • The poster presentation will showcase exploratory research conducted through Gennao’s ongoing collaboration with the laboratory of Peter M. Glazer, M.D., Ph.D., Chair of the Department of Therapeutic Radiology, Professor of Genetics and Robert E. Hunter Professor of Therapeutic Radiology at the Yale School of Medicine.
  • Specifically, the presentation will demonstrate the potential application of the GMAB platform as an antibody-drug conjugate (ADC) for the treatment of solid tumors.
  • The details of the poster presentation are as follows:
    Title: Targeted delivery of Exatecan to tumors via a novel cell-penetrating, anti-DNA antibody

Western Alliance Bank Bolsters Commercial and Industrial Team with Strategic Hires Katie McDowell and Jon VanDerMeid

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Defense, Aerospace, Manufacturing, Finance, Banking, Other Defense, Yale School of Management, Government, Investment management, Industrial, Business administration, C&I, Commercial, Senior, Credit, Michigan State University, Yale school, Multimedia, Financial services

Western Alliance Bank today announced the appointment of Katie McDowell and Jon VanDerMeid to the organization’s Commercial and Industrial Banking team.

Key Points: 
  • Western Alliance Bank today announced the appointment of Katie McDowell and Jon VanDerMeid to the organization’s Commercial and Industrial Banking team.
  • McDowell assumes the role of Senior Vice President, Relationship Manager to support the organization’s Aerospace, Defense and Government Services team, and VanDerMeid takes on the role of Credit Underwriting and Portfolio Manager, Commercial & Industrial to support the broader Commercial and Industrial team.
  • View the full release here: https://www.businesswire.com/news/home/20240327315080/en/
    Jon VanDerMeid, Western Alliance Bank, Aerospace & Defense Group (Photo: Business Wire)
    “In a strategic step that reaffirms our commitment to providing outstanding, customized commercial banking for our clients, we are thrilled to welcome Katie McDowell and Jon VanDerMeid to the Western Alliance Bank team,” said Matt Griesbach, Commercial and Industrial Industry Executive, Aerospace and Defense, at Western Alliance Bank.
  • VanDerMeid also joins the Western Alliance Bank team with two decades of industry experience, holding pivotal roles in commercial, leasing and investment banking underwriting.

SAPA-GP Hosted the 2024 Annual Conference Highlighting the Innovating Biopharma Frontier

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Health informatics, Informatics, COVID 19, McKinsey & Company, COVID, Conference, Data science, Spark Therapeutics, AI, Volunteering, Section, MBA, Yale School of Medicine, Therapy, Process, Drug development, Yale school, Multimedia, Proposition, Jazz Pharmaceuticals

On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.

Key Points: 
  • On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.
  • Fangning Zhang, MBA, Partner at McKinsey & Company, delivered the conference opening keynote speech “Path towards Value Creation – China Biopharma Innovation Trends”.
  • “Our conference has been very successful in capturing the latest trends foretelling the direction of biopharma industry.
  • The 2024 SAPA-GP Annual Conference was a great gathering of life scientists, pharmaceutical experts, and business leaders from diverse backgrounds, experiences, and accomplishments.

OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

Retrieved on: 
Tuesday, March 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, European Alliance, United, United Nations, Asthma, AAP, Yale school, CD74, Hôpital Cochin, Trinity College Dublin, Arthritis & Rheumatology, Molecular medicine, Cancer, University, Publication, Medical school, ASCI, Prognosis, Trinity, Pathology, Diagnosis, Public health, Trinity College, Arthritis, Physiology, Biomarker, Global Health, Nephritis, Society, EULAR, Inflammatory bowel disease, Physician, Pharmaceutical industry

OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

Key Points: 
  • OncoOne , a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
  • ON104 is a monoclonal antibody targeting the oxidized isoform of the macrophage migration inhibitory factor (oxMIF) for the treatment of chronic inflammatory diseases.
  • His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases.
  • Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024
Therapy, Reward, Alcoholism, Ministry, NET, Serotonin, Dopamine, Norepinephrine, Safety, MEAI, CWY, Patient, Clinical trial, Yale school, DAT, Psychiatry, Sheba Medical Center, Research, Pharmaceutical industry

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.